Deciphera's GIST therapy ripretinib wins speedy FDA review — setting the stage for battle with rival Blueprint
Blueprint Medicines has the edge on timing with its rival cancer drug Ayvakit, but Deciphera Pharmaceuticals is not far behind. On Wednesday, the Waltham …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
